A substantial modification, including the addition of a clinical trial site or the change of a principal investigator in the clinical trial site, may only be implemented if it has been approved in accordance with the procedure set out in this Chapter.
Home› Health & Pharmaceuticals› Clinical Trials Regulation
Chapter III · AUTHORISATION PROCEDURE FOR A SUBSTANTIAL MODIFICATION OF A CLINICAL TRIAL › Article 15
General principles
←→ also move between articles